EXELIXIS, INC. (EXEL) FY2026 Q2 Balance Sheet

Balance Sheet

As of 2026-07-03

Swipe to see the full flow
EXELIXIS, INC. (EXEL) FY2026 Q2 Balance SheetBalance sheet as of 2026-07-03. The chart shows assets, liabilities and equity at that date.Current liabilities$361.93 MCurrent assets$1.25 BLiabilities$650.47 MAssets$2.49 BNon-current liabilities$288.55 MEquity$1.84 BGross equity(calculated)$2.11 BNon-current assets$1.24 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable securitiesTrade receivables, netCash and cash equivalentsPrepaid expenses and other current assetsInventoryNon-current marketable securitiesDeferred tax assets, netRight-of-use assets and other non-current assetsProperty and equipment, netGoodwillOther current liabilitiesAccrued compensation and benefitsRebates and fees due to customersAccrued clinical trial liabilitiesAccounts payableAccrued collaboration liabilitiesNon-current operating lease liabilitiesOther non-current liabilitiesAdditional paid-in-capitalCommon stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive income (loss)Other current liabilitiesOther current liabilities$102.66 MAccrued compensation and benefitsAccrued compensation and benefits$68.63 MCurrent liabilitiesCurrent liabilities$361.93 MCurrent assetsCurrent assets$1.25 BRebates and fees due to customersRebates and fees due to customers$66.71 MMarketable securitiesMarketable securities$557.94 MAccrued clinical trial liabilitiesAccrued clinical trial liabilities$59.77 MLiabilitiesLiabilities$650.47 MAssetsAssets$2.49 BTrade receivables, netTrade receivables, net$322.21 MAccounts payableAccounts payable$39.06 MCash and cash equivalentsCash and cash equivalents$281.45 MAccrued collaboration liabilitiesAccrued collaboration liabilities$25.10 MNon-current liabilitiesNon-current liabilities$288.55 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$60.50 MNon-current operating lease liabilitiesNon-current operating lease liabilities$165.93 MEquityEquity$1.84 BInventoryInventory$28.73 MOther non-current liabilitiesOther non-current liabilities$122.62 MGross equity (calculated)Gross equity(calculated)$2.11 BNon-current assetsNon-current assets$1.24 BNon-current marketable securitiesNon-current marketable securities$544.93 MDeferred tax assets, netDeferred tax assets, net$294.21 MRight-of-use assets and other non-current assetsRight-of-use assets and other non-current assets$247.93 MAdditional paid-in-capitalAdditional paid-in-capital$2.11 BProperty and equipment, netProperty and equipment, net$92.67 MGoodwillGoodwill$63.68 MCommon stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectivelyCommon stock$249.00 KAccumulated deficitAccumulated deficit−$262.53 MAccumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)−$2.01 M
Chart details

EXELIXIS, INC. (EXEL) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-07-03. The chart shows assets, liabilities and equity at that date.

Assets
2,494,234,000 US dollars
Current assets
1,250,822,000 US dollars
Non-current assets
1,243,412,000 US dollars
Liabilities
650,472,000 US dollars
Current liabilities
361,927,000 US dollars
Non-current liabilities
288,545,000 US dollars
Equity
1,843,762,000 US dollars
Marketable securities
557,937,000 US dollars
Trade receivables, net
322,213,000 US dollars
Cash and cash equivalents
281,448,000 US dollars
Prepaid expenses and other current assets
60,495,000 US dollars
Inventory
28,729,000 US dollars
Non-current marketable securities
544,930,000 US dollars
Deferred tax assets, net
294,205,000 US dollars
Right-of-use assets and other non-current assets
247,928,000 US dollars
Property and equipment, net
92,665,000 US dollars
Goodwill
63,684,000 US dollars
Other current liabilities
102,662,000 US dollars
Accrued compensation and benefits
68,629,000 US dollars
Rebates and fees due to customers
66,711,000 US dollars
Accrued clinical trial liabilities
59,767,000 US dollars
Accounts payable
39,062,000 US dollars
Accrued collaboration liabilities
25,096,000 US dollars
Non-current operating lease liabilities
165,929,000 US dollars
Other non-current liabilities
122,616,000 US dollars
Additional paid-in-capital
2,108,059,000 US dollars
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 248,885 and 262,483 at June 30, 2026, and December 31, 2025, respectively
249,000 US dollars
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued
0 US dollars
Accumulated deficit
negative 262,533,000 US dollars
Accumulated other comprehensive income (loss)
negative 2,013,000 US dollars
Gross equity (calculated)
2,108,308,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
EXELIXIS, INC. (EXEL) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!